Dublin, September 4th 2018 – The organizers of the International Conference of Drug Regulatory Authorities (ICDRA)[[http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/en/]] 2018 invited the DCVMN regulatory expert working group to join the pre-ICDRA session on “Enabling access to innovative medical products in resource-limited settings” and present the recently published study, conducted in collaboration with IFPMA [[https://www.ifpma.org]], on the challenges for the registration of vaccines in emerging countries [[https://www.ncbi.nlm.nih.gov/pubmed/29724510 ]]. A DCVMN representative, Ms. Iin Susanti, delivered the lecture and participated in a panel discussion, elaborating on opportunities and future options for regulatory convergence in addressing the challenges, while respecting regulatory requirements.
Since 1980, ICDRA has been instrumental in providing a forum for drug regulatory authorities of WHO Member States to meet with interested stakeholders and discuss new ways to strengthen collaboration in national and international regulation and improve the safety, efficacy and quality of medicines, vaccines, biomedicines and herbal products.
The conferences, established by WHO as a platform to develop international consensus, promote exchange of information and collaborative approaches to issues of common concern.
DCVMN commends ICDRA for serving as an important instrument for WHO and drug regulatory authorities in their efforts to harmonize regulation of medicinal products.
